Background: The ESHAP regimen has been show an efficacious salvage therapy for refractory non Hodgkin's lymphoma. Object: Evaluate the clinical efficacy and toxicity of ESHAP regimen. Subjects and Method: Subject: Patients with refractory non Hodgkin's lymphoma have been agreed to use ESHAP regimen.